Challenges in Catalysis IX

Synopsis

SCI’s Fine Chemicals Group and RSC’s Applied Catalysis Group are pleased to announce this one-day biennial symposium - Challenges in Catalysis for Pharmaceuticals and Fine chemicals IX. The aim of this meeting, well-supported both by industry and academia is to debate the current developments in catalysis, where they are going and what industry needs.  An exciting line up of leading academic and industrial scientists will present a series of lectures covering topics in homogeneous, heterogeneous and enzymatic catalysis.

---

Attendees

This meeting is suitable for all organic/medicinal chemists (students, early and mid-career) working in academia and industry and chemical engineers in process development.

---

Programme

The programme will be confirmed in due course.

SCI’s Fine Chemicals Group are committed to promoting diversity and equality in the chemical sciences. We aim to identify high quality speakers for all our conferences with full inclusivity where attendees from all backgrounds are welcome. We are open to offering flexible presentation options.

---

Call for posters

If you would like to present a poster, please send an abstract of maximum one A4 page or up to 300 words, indicating title and authors, to conferences@soci.org by Wednesday 16 September 2025 with the subject line “Challenges in Catalysis IX – poster abstract submission”. You can download an Abstract_Template.

---

Sponsorship information

Please see the sponsorship pack and email conferences@soci.org to let us know which package you are interested in.

---

Accessibility Grants

SCI accessibility grants are available to support SCI members with disabilities, long term health conditions, those who require a carer, and members who are nursing parents to attend SCI events. Download an application form to apply for a grant.

---

Venue and Contact

---

Booking Process/Deadlines

Booking terms and conditions

---

---

Organising committee

Emmanuel Callens, 30Technology 
Sarah Facchetti, Johnson Matthey 
Sam Staniland, AstraZeneca
Katherine Wheelhouse, GSK 

---